Phase 1/2a Open-label Dose Safety, Reactogenicity, Immunogenicity and Efficacy of the Candidate Plasmodium Vivax Malaria Protein 001 (VMP001) Administered Intramuscularly With GSK Biologicals Adjuvant System AS01B in Healthy Malaria-Naive Adults.
Phase of Trial: Phase I/II
Latest Information Update: 19 Jun 2012
At a glance
- Drugs Plasmodium vivax CS protein vaccine (Primary) ; AS01B
- Indications Malaria
- Focus Adverse reactions
- 19 Jun 2012 Actual patient number is 48 according to ClinicalTrials.gov.
- 19 Jun 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
- 19 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.